Clinical Trial Update: Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial compares Ivonescimab alone or Ivonescimab with Ligufalimab versus Pembrolizumab for head and neck squamous cell carcinoma; recruitment …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Ivonescimab (AK112/SMT112)
• KEYTRUDA (PEMBROLIZUMAB)
• Ligufalimab

Snippet

Sponsor: Groupe Oncologie Radiotherapie Tete et Cou | Conditions: Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | Phase 3 | Status: NOT_YET_RECRUITING